Cargando…

Discovery of an Allosteric Binding Site in Kinetoplastid Methionyl-tRNA Synthetase

[Image: see text] Methionyl-tRNA synthetase (MetRS) is a chemically validated drug target in kinetoplastid parasites Trypanosoma brucei and Leishmania donovani. To date, all kinetoplastid MetRS inhibitors described bind in a similar way to an expanded methionine pocket and an adjacent, auxiliary poc...

Descripción completa

Detalles Bibliográficos
Autores principales: Torrie, Leah S., Robinson, David A., Thomas, Michael G., Hobrath, Judith V., Shepherd, Sharon M., Post, John M., Ko, Eun-Jung, Ferreira, Rafael Alves, Mackenzie, Claire J., Wrobel, Karolina, Edwards, Darren P., Gilbert, Ian H., Gray, David W., Fairlamb, Alan H., De Rycker, Manu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294809/
https://www.ncbi.nlm.nih.gov/pubmed/32275825
http://dx.doi.org/10.1021/acsinfecdis.9b00453
Descripción
Sumario:[Image: see text] Methionyl-tRNA synthetase (MetRS) is a chemically validated drug target in kinetoplastid parasites Trypanosoma brucei and Leishmania donovani. To date, all kinetoplastid MetRS inhibitors described bind in a similar way to an expanded methionine pocket and an adjacent, auxiliary pocket. In the current study, we have identified a structurally novel class of inhibitors containing a 4,6-diamino-substituted pyrazolopyrimidine core (the MetRS02 series). Crystallographic studies revealed that MetRS02 compounds bind to an allosteric pocket in L. major MetRS not previously described, and enzymatic studies demonstrated a noncompetitive mode of inhibition. Homology modeling of the Trypanosoma cruzi MetRS enzyme revealed key differences in the allosteric pocket between the T. cruzi and Leishmania enzymes. These provide a likely explanation for the lower MetRS02 potencies that we observed for the T. cruzi enzyme compared to the Leishmania enzyme. The identification of a new series of MetRS inhibitors and the discovery of a new binding site in kinetoplastid MetRS enzymes provide a novel strategy in the search for new therapeutics for kinetoplastid diseases.